GILD Volume Alert - GILD 108.48 Gilead Sciences $GILD Hit a high of 108.51 Currently 11:15 Last price 108.48 +1.46 +1.36% With a day low of 106.67 and a current volume of 4,651,187.
GILD Gilead Sciences Recent Headline News
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 108.47 (+1.45), MRK: 59.69 (+0.88)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 56 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.47 (+1.45), ACHN: 12.83 (-0.02), MRK: 59.69 (+0.88), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 1 hr 6 mins ago
JNJ: 109.02 (+0.20), GILD: 108.47 (+1.45), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - 1 hr 24 mins ago
VRTX: 117.65 (+0.71), GILD: 108.48 (+1.46), MRK: 59.69 (+0.88), DNDN: 0.16 (-0.02), AZN: 74.09 (+0.88), TEVA: 58.50 (+0.46), ABBV: 64.03 (+0.24), GSK: 45.78 (+0.62), BMY: 58.97 (+0.16), NVS: 92.50 (-0.13)
Early Glance: Biotechnology companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 108.48 (+1.46), AMGN: 163.44 (+0.35), CELG: 108.28 (+0.27)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 59 mins ago
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 390.24 (+2.97), YHOO: 48.36 (-1.05), AMZN: 309.65 (+4.54), BIIB: 327.20 (-0.67), VRTX: 117.61 (+0.67), FEYE: 32.18 (-0.21), LNKD: 228.07 (-1.18), EBAY: 54.15 (+0.26), GILD: 108.50 (+1.48), AMGN: 163.44 (+0.35), ABBV: 64.03 (+0.24), REGN: 396.87 (+10.90), CELG: 108.28 (+0.27)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 2 hrs 2 mins ago
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 31 mins ago
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), LGND: 57.71 (+2.03), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), LGND: 57.71 (+2.03), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), BMY: 58.97 (+0.16)
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
Business Wire - Tue Nov 11, 7:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi(R) by the U.S. Food and Drug Administration in December 2013, and the investigational NS5A inhibitor GS-5816 for the treatment of chronic hepatitis C virus (HCV) infection. These data are being presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting(R) 2014) in Boston.
GILD: 108.50 (+1.48)
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
Business Wire - Tue Nov 11, 7:01AM CST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals. These data will be presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting2014) in Boston.
GILD: 108.50 (+1.48)
Jim Cramer's Top Stock Picks: WWAV GILD BABA
at The Street - Tue Nov 11, 5:00AM CST
Cramer says investors looking for long-term investments need to stick with companies that have long-term themes going in their favor.
WWAV: 36.53 (+0.53), WFM: 47.60 (-0.45), CLX: 101.02 (-0.65), GILD: 108.50 (+1.48), EOG: 97.84 (-0.66), BABA: 114.87 (-4.28)
Cramer's Mad Money - Disney Is A Sleep At Night Stock (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:09AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 10. Disney (NYSE: DIS ) Is A Sleep At Night Stock. Other stocks mentioned: Baidu (NASDAQ: BIDU ), Vipshop (NYSE: VIPS ), Alibaba (NYSE: BABA ),...
WFM: 47.60 (-0.45), VIPS: 24.22 (-0.29), CLX: 101.02 (-0.65), XOM: 95.96 (-0.32), DIS: 89.60 (-0.18), BBY: 35.01 (+0.30), TM: 119.34 (+1.37), CELG: 108.28 (+0.27), WWAV: 36.53 (+0.53), JNJ: 109.02 (+0.20), BIDU: 245.31 (-2.27), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), EOG: 97.84 (-0.66), MCD: 95.34 (+0.23), CVX: 118.01 (+0.09), AAPL: 108.71 (-0.12), BABA: 114.87 (-4.28)
Market Maker Surveillance Report. GILD, QCOM, SAN, MNKD, HST, BABA, Bullishly Biased Price Friction For Monday, November 10th 2014
M2 - Tue Nov 11, 2:31AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4913 companies with "abnormal" market making, 2783 companies with positive Friction Factors and 2128 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), Qualcomm Inc (NASDAQ:QCOM), Banco Santander SA (NYSE:SAN), Mannkind Corp (NASDAQ:MNKD), Host Hotels and Resorts Inc (NYSE:HST), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SAN: 8.40 (+0.10), HST: 22.81 (+0.05), GILD: 108.50 (+1.48), QCOM: 69.30 (-0.06), MNKD: 6.06 (+0.18), BABA: 114.88 (-4.27)
Jim Cramer's 'Mad Money' Recap: WWAV, GILD, BABA, AMZN
at The Street - Mon Nov 10, 7:38PM CST
Cramer says home gamers will never be able to beat the professional day traders but sticking with long-term themes can pay an annuity for many many years.
KMI: 38.50 (unch), AMZN: 309.64 (+4.53), GD: 141.83 (+1.01), LMT: 187.93 (+0.94), CLX: 101.02 (-0.65), RTN: 104.00 (+0.48), NOC: 137.49 (+1.84), DIS: 89.60 (-0.18), INTC: 33.40 (+0.14), WWAV: 36.53 (+0.53), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), SSYS: 102.41 (-2.48), AAPL: 108.71 (-0.12), BABA: 114.88 (-4.27)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 108.50 (+1.48), AMGN: 163.44 (+0.35), CELG: 108.28 (+0.27)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.20 (-0.67), GILD: 108.50 (+1.48), SHPG: 201.95 (+0.97), ABBV: 64.03 (+0.24), CELG: 108.28 (+0.27)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.68 (+0.44), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), ABBV: 64.03 (+0.24)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02)
GILD Gilead Sciences Recent Headline News
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 108.47 (+1.45), MRK: 59.69 (+0.88)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 56 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.47 (+1.45), ACHN: 12.83 (-0.02), MRK: 59.69 (+0.88), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 1 hr 6 mins ago
JNJ: 109.02 (+0.20), GILD: 108.47 (+1.45), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - 1 hr 24 mins ago
VRTX: 117.65 (+0.71), GILD: 108.48 (+1.46), MRK: 59.69 (+0.88), DNDN: 0.16 (-0.02), AZN: 74.09 (+0.88), TEVA: 58.50 (+0.46), ABBV: 64.03 (+0.24), GSK: 45.78 (+0.62), BMY: 58.97 (+0.16), NVS: 92.50 (-0.13)
Early Glance: Biotechnology companies
AP - 52 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 108.48 (+1.46), AMGN: 163.44 (+0.35), CELG: 108.28 (+0.27)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 59 mins ago
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 390.24 (+2.97), YHOO: 48.36 (-1.05), AMZN: 309.65 (+4.54), BIIB: 327.20 (-0.67), VRTX: 117.61 (+0.67), FEYE: 32.18 (-0.21), LNKD: 228.07 (-1.18), EBAY: 54.15 (+0.26), GILD: 108.50 (+1.48), AMGN: 163.44 (+0.35), ABBV: 64.03 (+0.24), REGN: 396.87 (+10.90), CELG: 108.28 (+0.27)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 2 hrs 2 mins ago
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 31 mins ago
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), MRK: 59.69 (+0.88), LGND: 57.71 (+2.03), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 109.02 (+0.20), GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02), CNAT: 6.99 (-0.07), LGND: 57.71 (+2.03), RGLS: 20.25 (-0.66), ABBV: 64.03 (+0.24), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), BMY: 58.97 (+0.16)
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
Business Wire - Tue Nov 11, 7:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi(R) by the U.S. Food and Drug Administration in December 2013, and the investigational NS5A inhibitor GS-5816 for the treatment of chronic hepatitis C virus (HCV) infection. These data are being presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting(R) 2014) in Boston.
GILD: 108.50 (+1.48)
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
Business Wire - Tue Nov 11, 7:01AM CST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals. These data will be presented this week at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting2014) in Boston.
GILD: 108.50 (+1.48)
Jim Cramer's Top Stock Picks: WWAV GILD BABA
at The Street - Tue Nov 11, 5:00AM CST
Cramer says investors looking for long-term investments need to stick with companies that have long-term themes going in their favor.
WWAV: 36.53 (+0.53), WFM: 47.60 (-0.45), CLX: 101.02 (-0.65), GILD: 108.50 (+1.48), EOG: 97.84 (-0.66), BABA: 114.87 (-4.28)
Cramer's Mad Money - Disney Is A Sleep At Night Stock (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:09AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 10. Disney (NYSE: DIS ) Is A Sleep At Night Stock. Other stocks mentioned: Baidu (NASDAQ: BIDU ), Vipshop (NYSE: VIPS ), Alibaba (NYSE: BABA ),...
WFM: 47.60 (-0.45), VIPS: 24.22 (-0.29), CLX: 101.02 (-0.65), XOM: 95.96 (-0.32), DIS: 89.60 (-0.18), BBY: 35.01 (+0.30), TM: 119.34 (+1.37), CELG: 108.28 (+0.27), WWAV: 36.53 (+0.53), JNJ: 109.02 (+0.20), BIDU: 245.31 (-2.27), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), EOG: 97.84 (-0.66), MCD: 95.34 (+0.23), CVX: 118.01 (+0.09), AAPL: 108.71 (-0.12), BABA: 114.87 (-4.28)
Market Maker Surveillance Report. GILD, QCOM, SAN, MNKD, HST, BABA, Bullishly Biased Price Friction For Monday, November 10th 2014
M2 - Tue Nov 11, 2:31AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4913 companies with "abnormal" market making, 2783 companies with positive Friction Factors and 2128 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), Qualcomm Inc (NASDAQ:QCOM), Banco Santander SA (NYSE:SAN), Mannkind Corp (NASDAQ:MNKD), Host Hotels and Resorts Inc (NYSE:HST), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SAN: 8.40 (+0.10), HST: 22.81 (+0.05), GILD: 108.50 (+1.48), QCOM: 69.30 (-0.06), MNKD: 6.06 (+0.18), BABA: 114.88 (-4.27)
Jim Cramer's 'Mad Money' Recap: WWAV, GILD, BABA, AMZN
at The Street - Mon Nov 10, 7:38PM CST
Cramer says home gamers will never be able to beat the professional day traders but sticking with long-term themes can pay an annuity for many many years.
KMI: 38.50 (unch), AMZN: 309.64 (+4.53), GD: 141.83 (+1.01), LMT: 187.93 (+0.94), CLX: 101.02 (-0.65), RTN: 104.00 (+0.48), NOC: 137.49 (+1.84), DIS: 89.60 (-0.18), INTC: 33.40 (+0.14), WWAV: 36.53 (+0.53), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), SSYS: 102.41 (-2.48), AAPL: 108.71 (-0.12), BABA: 114.88 (-4.27)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 108.50 (+1.48), AMGN: 163.44 (+0.35), CELG: 108.28 (+0.27)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.20 (-0.67), GILD: 108.50 (+1.48), SHPG: 201.95 (+0.97), ABBV: 64.03 (+0.24), CELG: 108.28 (+0.27)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.68 (+0.44), GILD: 108.50 (+1.48), MRK: 59.68 (+0.87), ABBV: 64.03 (+0.24)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.50 (+1.48), ACHN: 12.83 (-0.02)
